Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Erik Portelius

 

Erik Portelius PhD

 

 

 

 

 

 

 

 

Erik Portelius, Ph.D
E-mail: erik.portelius@neuro.gu.se
Tel (office): +46 31 343 2390

CURRICULUM VITAE


 


CURRENT POSITION


Biochemist at the research team on “Neurochemical Pathogenesis and Diagnostics” at the Dept. of Neuroscience and Physiologi, University of Gothenburg, Sweden.

EDUCATION AND SCIENTIFIC MERITS


Master degree in analytical chemistry (MSc), University of Karlstad 2001
Doctor in Medical Science (PhD), Göteborg University 2009

RESEARCH INTEREST


The major research interests are:
* Method development for studies on cerebrospinal fluid biochemical markers for clinical diagnosis of AD
* Mass spectrometry
* Targeted proteomics

SCIENTIFIC PRODUCTION


Publications
• About 15 publications (original research papers in peer-reviewed journals).
• About 5 reviews in peer-reviewed journals.

Selected publictaions (see also under Publications for the research team)
• Portelius, E; Westman-Brinkmalm, A; Zetterberg, H; Blennow, K. Determination of ß-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. Journal of proteome research. 5, 1010-1016, 2006

• Portelius, E; Price, E; Brinkmalm, G; Stiteler, M; Olsson, M; Persson, R; Westman-Brinkmalm, A; Zetterberg, H; Simon, AJ; Blennow, K. A novel pathway for amyloid precursor protein processing. Neurobiol Aging, doi:10.1016/j.neurobiolaging.2009.06.002, 2009

• Portelius, E; Dean, RA; Gustavsson, MK; Andreasson, U; Zetterberg, H; Siemers, E; Blennow K. Amyloid beta isoforms in CSF reflect gamma- secretase inhibition in Alzheimer’s disease. Alzheimer´s disease and therapy. 2(2) 7, 2010


RESEARCH STUDENTS

 

Co-supervisor
• Ai Jun Tran, 2007, ” Investigation of the degrading pattern related to the amyloid precursor protein in cerebrospinal fluid”. Master thesis in Pharmaceutical Bioscience, 20p

CONGRESSES

 

Oral presentation
• The International Conference on Alzheimer´s Disease and related Disorders, Hawaii, USA, 2010. “Acute effect on novel Abeta isoforms in cerebrospinal fluid as a response to treatment with gamma-secretase inhibitors and modulators in Alzheimer’s disease”

• The International conference on Alzheimer´s disease and Parkinson’s disease. Salzburg, Austria, 2007, “Cerebrospinal fluid ß-amyloid fragment signatures in neurodegenerative diseases”

• The International Conference on Alzheimer´s Disease and related Disorders, Madrid, Spain, 2006. “Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry”

Poster presentation
• 11th International Conference on Alzheimer´s Disease and related Disorders, Chicago, USA, 2008
“Identification of novel APP/Ab isoforms in human cerebrospinal fluid”

• Proceedings of the 54nd Annual Conference on Mass Spectrometry and Allied Topics, Seattle, USA, 2006. “Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry”

• Proceedings of the 52nd Annual Conference on Mass Spectrometry and Allied Topics, Nashville, USA, 2004. “Probing temperature changes in the electrospray plume using laser-induced fluorescence spectrometry”

• Proceedings of the 51nd Annual Conference on Mass Spectrometry and Allied Topics, Montreal, Canada, 2003. “Characterization of Alzheimer's amyloid fibrils with electrospray mass spectrometry using hydrogen exchange on proline mutant fibrils”

SCIENTIFIC AWARDS


• Best thesis at the institute of Neuroscience and Physiology, the Sahlgrenska Academy, 2009

• The Phabian award, best thesis - honorory mention, 2009

• Travel Fellowship for the 13th International Conference on Alzheimer’s Disease (ICAD) in Honolulu, Hawaii, 2010

 

Sidansvarig: Staffan Persson|Sidan uppdaterades: 2010-09-03
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?